ArticleDiscover oncology2025
Bioinformatics exploration of the S1PR1 receptor in various human cancers and its clinical relevance.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Label-free cell phenotypic profiling of sphingosine-1-phosphate receptor 1 and discovery of its agonist from natural products.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Decoding the S1P-S1PR axis in cancer: Mechanisms, pathways and therapeutic horizons (Review).Biomedical reports · 2026Review
- Review
- Pan-cancer signaling landscape linked to endothelial and immune Sphingosine-1-phosphate receptor 1 (S1PR1) expression.In silico pharmacology · 2026Article
- ATP11B triggers the infiltration of T cells into GBM and intensifies anti-GBM immunity by upregulating and externalizing S1PR1.Journal of translational medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveS1PR1 (sphingosine-1-phosphate receptor 1) plays a critical role in key cancer-related processes such as cell migration, proliferation, and survival. While its functions are well-established in the cardiovascular and immune systems, its mechanism in cancer remains unclear. Our study aims to investigate the expression, mutations, post-translational modifications, and immune infiltration of S1PR1 across different cancers, and particularly focus on its potential as a therapeutic target and prognostic biomarker.
methodsWe utilized HPA, GTEx, TCGA and CPTAC bioinformation databases to evaluate the expression level of S1PR1 between normal and cancer tissue. Sequence conservation and phylogenetic analysis of S1PR1 are assessed by NCBI and Pfam database. Gene mutations, methylation, phosphorylation, and immune infiltration of S1PR1 were analyzed by cBioPortal, MethSuv, CPTAC and TIMER2.0 respectively.
resultsS1PR1 expression varied significantly among cancers, with decreased levels in bladder and breast cancers, and increased levels in renal cell carcinoma, thyroid cancer, and acute myeloid leukemia. Mutation analysis revealed frequent mutations in endometrial, lung, and ovarian cancers. Reduced methylation in lung adenocarcinoma correlated with improved survival. Elevated phosphorylation was observed in glioblastoma and renal carcinoma. Immune infiltration analysis showed significant correlations with CAFs and γδ T cells.
conclusionS1PR1 plays a critical role in cancer progression through its expression, mutations, and modifications. These findings suggest that S1PR1 could be served as a potential biomarker and therapeutic target in cancer, but it need a further validation in clinical settings is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.